Streetbeat News

RAPP

Rapport Therapeutics Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

10.43

Mkt cap

384M

Volume

186K

High

11.34

P/E Ratio

-2.78

52-wk high

29.74

Low

10.29

Div yield

N/A

52-wk low

6.43

Rapport Therapeutics reported its Q4 and full-year 2024 financial results, highlighting the potential of RAP-219 for epilepsy and CNS disorders. The company plans to initiate a Phase 2a trial for bipolar mania in 2025 and has appointed Dr. Jeffrey Sevigny as CMO. Rapport ended 2024 with $305.3 million in cash, expected to fund operations through 2026.

Portfolio Pulse from

March 11, 2025 | 11:15 am

Rapport Therapeutics has appointed Dr. Jeffrey Sevigny as Chief Medical Officer to enhance its clinical strategy and precision medicine development for CNS disorders.

Portfolio Pulse from

March 03, 2025 | 12:15 pm

Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotech company, will present at two investor conferences in March 2025, including the TD Cowen 45th Annual Health Care Conference in Boston.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

Rapport Therapeutics has presented data showing a strong correlation between reductions in long episodes and clinical seizures, supporting the potential of their drug RAP-219 for treating focal epilepsy. The ongoing Phase 2a trial's primary endpoint is the change in long episode frequency, with results expected in mid-2025.

Portfolio Pulse from

December 06, 2024 | 5:15 pm

Rapport Therapeutics is set to present data at the American Epilepsy Society Annual Meeting, including findings from a Phase 2a trial on seizure biomarkers, as well as preclinical and Phase 1 clinical data.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

Several Wall Street analysts have initiated coverage on various stocks with positive ratings. Notably, PureCycle Technologies, ChoiceOne Financial Services, Rapport Therapeutics, Neonode, and Global Self Storage received Buy or Overweight ratings with significant price targets above their current trading prices.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 2:51 pm

Jones Trading has initiated coverage on Rapport Therapeutics with a Buy rating and set a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.